Table 3 Tau therapeutics in phase II (as of February 28, 2023)
From: The therapeutic landscape of tauopathies: challenges and prospects
Molecule type | Company name | Drug name | Indication | Route of administration | Mechanism of action |
|---|---|---|---|---|---|
ASO | Biogen | BIIB 080 (IONIS-MAPTRx) | AD, dementia associated with AD | Intrathecal | ASO acts by targeting tau/MAPT. |
mAb | Genentech | Semorinemab | AD | IV, parenteral | Anti-tau mAb acts by targeting misfolded tau. |
Johnson & Johnson | JNJ-3657 (JNJ-63733657) | AD, dementia | IV | A mAb that targets p-tau. | |
UCB Biopharma | Bepranemab (UCB-0107, RG 6416) | PSP, AD, tauopathies | IV | Recombinant humanized IgG4P. | |
Plasma protein fraction | Alkahest | GRF-6019 (ALK 6019) | AD | IV | Proprietary plasma fractions replenish the positive functional chronokines that decrease with age. |
Protein | INmune Bio | Pegipanermin (XProâ„¢; XPro1595; DN-TNF; INB 03) | AD | Subcutaneous | TNFR1 antagonist, prevents differentiation and function of myeloid-derived suppressor cells. |
Small molecule | Asceneuron | ASN120290 (ASN-561, ASN90) | PSP | Oral | Protein O-GlcNAcase inhibitor. |
EIP Pharma | Neflamapimod (VX 745) | AD | Oral | Inhibitor of the alpha isoform of the protein enzyme p38 mitogen-activated protein kinase (p38 MAPK alpha). | |
Eli Lilly and Co | LY-3372689 | AD | Oral | Protein O-GlcNAcase inhibitor. | |
Oryzon Genomics SA | Vafidemstat (ORY-2001, CNS optimized LSD1 inhibitor) | AD | Oral | Inhibitor of monoamine oxidase type B (MAO-B) and lysine-specific demethylase 1 (LSD1, KDM1A). | |
PharmatrophiX | LM-11A31BHS | AD | Oral | Blocks the interaction between beta-amyloid peptide and p75NTR, down-regulating the signaling pathways and up-regulating survival signaling. | |
reMYND | REM-0046127 (ReS-19Â T) | AD | Oral | Restores calcium dyshomeostasis. | |
T3D Therapeutics | T3D-959 | AD | Oral | Dual agonist of the peroxisome proliferator-activated nuclear receptor delta/gamma, aka PPARδ/γ (metabolism/glycolytic pathways). | |
Univ. of California, Irvine | Nicotinamide | AD | Oral | Histone deacetylase inhibitor to reduce tau-induced microtubule depolymerization and tau phosphorylation. | |
Vivoryon Therapeutics N.V | Varoglutamstat (PQ912) | AD | Oral | Blocks the enzyme glutaminyl cyclase (QPCT), which catalyzes the formation of N3pE amyloid. In addition, QPCTL, an isoform of QPCT, is also required for the stability and full potency of the proinflammatory protein CCL2, reducing neuroinflammation. CCL2 is also a promoter of tau pathology. | |
Vaccine | AC Immune SA (in collaboration with Janssen) | JACI-35054; ACI-35030 (ACI-35, Anti-p-tau vaccine; liposomal anti-p-tau vaccine) | AD, tauopathies | Parenteral | Immune stimulator. Liposomal vaccine based on SupraAntigen technology platform administered through parenteral route. Targets p-tau. |